Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1060993

CCN(CC)CCNC(=O)c1sc2c(c1OCc1ccncc1)c(=O)n(C)c1ccccc21.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 8/20 0.44
ALDH1A1 P00352 5/20 0.44
TSHR P16473 3/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 4/20 0.44
ALOX15 P16050 1/20 0.44
TP53 P04637 4/20 0.44
MAPT P10636 3/20 0.41
EGFR P00533 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.40
UBE2N P61088 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
POLB P06746 1/20 0.38
ACKR3 P25106 1/20 0.38
CREBBP Q92793 1/20 0.38
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1062326 0.95 KMT2A (0.53) KMT2AKDM4EALDH1A1TSHRHPGD
SCHEMBL10314384 0.95 KMT2A (0.55) KMT2AKDM4EALDH1A1TSHRHPGD
Trifluoroacetic Acid SCHEMBL1062645 0.91 KMT2A (0.39) KMT2AKDM4EALDH1A1TSHRHPGD
Trifluoroacetic Acid SCHEMBL1062118 0.90 RXFP1 (0.42) KMT2AKDM4EALDH1A1TSHRHPGD
SCHEMBL10314350 0.90 KMT2A (0.58) KMT2AKDM4EALDH1A1TSHRHPGD
Trifluoroacetic Acid SCHEMBL1062244 0.90 TP53 (0.45) KMT2AKDM4EALDH1A1HPGDMAPK1
Trifluoroacetic Acid SCHEMBL1062388 0.90 MAPT (0.42) KMT2AKDM4EALDH1A1HPGDHSD17B10
Trifluoroacetic Acid SCHEMBL1063314 0.88 SGMS2 (0.41) KMT2AKDM4EALDH1A1TSHRHPGD
Trifluoroacetic Acid SCHEMBL1064404 0.87 KMT2A (0.53) KMT2AKDM4EALDH1A1TSHRHPGD
Trifluoroacetic Acid SCHEMBL1061961 0.87 HDAC6 (0.44) KMT2AKDM4EALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247588-B1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-04-13 EP disclosed
US-8399449-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-03-19 US disclosed
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KMT2A 453/4885KDM4E 528/4885ALDH1A1 745/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KMT2A 386/4885KDM4E 464/4885ALDH1A1 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.